Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Trastuzumab/曲妥珠单抗 细胞实验
Cell Line
Concentration
Treated Time
Description
References
H9c2 rat cardiomyocytes
0, 0.2, 0.5, 1, 10 µM
12, 24, 48 hours
To investigate the effects of trastuzumab on H9c2 cell viability and oxidative stress. Results showed that trastuzumab reduced H9c2 cell viability and increased intracellular and mitochondrial ROS levels in a dose- and time-dependent manner.
Int J Mol Med. 2022 Feb;49(2):17
JIMT-1
0, 1, 2, 5, 10, 20, 50, 100 μg/mL
72 hours
Evaluate the effect of trastuzumab on the viability of JIMT-1 cells
Mol Cancer. 2023 Jan 10;22(1):6
SKBR3
0, 0.5, 1, 2, 5, 10, 20, 40 μg/mL
72 hours
Evaluate the effect of trastuzumab on the viability of SKBR3 cells
Mol Cancer. 2023 Jan 10;22(1):6
DD282
0.1 µM
72 hours
Testing the effect of trastuzumab on DD282 cells with HER2 variant of unknown significance, resulting in a viability decrease to 85.6%.
Gut. 2019 Feb;68(2):207-217
DD109
0.1 µM
72 hours
Testing the effect of trastuzumab on DD109 cells with HER2 amplification, resulting in a viability decrease to 79.2%.
Gut. 2019 Feb;68(2):207-217
DD107
0.1 µM
72 hours
Testing the effect of trastuzumab on DD107 cells with HER2 activating mutation, resulting in a viability decrease to 70.6%.
Gut. 2019 Feb;68(2):207-217
SNU216
10 μg/mL
48 hours
To evaluate the effect of trastuzumab on the proliferation of SNU216 cells. The results showed that trastuzumab or GLS1 inhibitors alone did not significantly affect the proliferation of trastuzumab-resistant cells, while the combination of BPTES or CB839 with trastuzumab partially inhibited the proliferation of trastuzumab-resistant cells.
Cancer Commun (Lond). 2023 Aug;43(8):909-937.
NCI-N87
10 μg/mL
48 hours
To evaluate the effect of trastuzumab on the proliferation of NCI-N87 cells. The results showed that trastuzumab or GLS1 inhibitors alone did not significantly affect the proliferation of trastuzumab-resistant cells, while the combination of BPTES or CB839 with trastuzumab partially inhibited the proliferation of trastuzumab-resistant cells.
Cancer Commun (Lond). 2023 Aug;43(8):909-937.
Trastuzumab/曲妥珠单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Nude mice
HER2-positive breast cancer xenograft model
Intraperitoneal injection
10 mg/kg
Every 5 days for 4 times
Evaluate the effect of trastuzumab on the growth of HER2-positive breast cancer xenografts
Mol Cancer. 2023 Jan 10;22(1):6
Nude mice
NCI-N87/luc tumor xenograft model
Intraperitoneal
Trastuzumab (10 mg/kg), TFBG (50 mg/kg)
Trastuzumab twice weekly for 3 weeks; TFBG daily for 21 days
To evaluate the efficacy of TFBG combined with trastuzumab in HER2-positive gastric cancer. Results showed that combination therapy significantly inhibited tumor growth and induced tumor regression.
搜索
